FBLG Q4 2023 Earnings — FibroBiologics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

FBLGFibroBiologics, Inc. Common Stock

$17M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$2M

Net Income

-$10M

EPS (Diluted)

$-0.31

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$432,000

Balance Sheet

Total Assets

$12M

Total Liabilities

$11M

Stockholders' Equity

$1M

Cash & Equivalents

$9M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$2M	-$1M	-90.2%
Net Income	-$10M	-$2M	-537.6%